导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.08% | 1202/4775 |
| 近一周 | -2.90% | 3929/5468 |
| 近一月 | 0.80% | 2078/5401 |
| 近一季 | -5.26% | 2381/5193 |
| 近半年 | -1.97% | 2718/4905 |
| 近一年 | 19.43% | 961/4330 |
| 近两年 | 71.54% | 922/2947 |
| 近三年 | 37.98% | 727/2226 |
| 成立以来 | 74.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.10% 1059/4961 |
20.55% 1221/5312 |
- - |
- - |
| 2025 | 35.54% 984/4813 |
3.69% 1052/3635 |
3.08% 1176/4076 |
23.51% 1536/4524 |
2.67% 884/4813 |
| 2024 | 3.25% 1935/3463 |
-1.94% 1300/2808 |
-3.63% 1402/3014 |
10.16% 2646/3129 |
-0.82% 1524/3463 |
| 2023 | -8.69% 1048/2656 |
6.27% 704/2280 |
-5.36% 1435/2385 |
-4.21% 1093/2515 |
-5.22% 1293/2655 |
| 2022 | -15.72% 428/2207 |
-10.00% 372/1919 |
5.52% 887/2016 |
-10.69% 440/2113 |
-0.62% 1630/2208 |
| 2021 | 17.13% 245/1822 |
3.31% 187/1255 |
7.98% 654/1330 |
4.68% 327/1466 |
0.30% 1139/1822 |
| 2020 | - - |
- - |
18.83% 321/1067 |
9.10% 671/1164 |
2.14% 1007/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 嘉实中证500指数增强A VS. 长安沪深300非周期A(740101) |